Clinical Trial Detail

NCT ID NCT03620019
Title Denosumab + Pembrolizumab in Patients With Stage IV Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

melanoma

Therapies

Denosumab + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.